Gilead's 4-drug combo shows early promise against hepatitis C

03/8/2011 | Bloomberg

A four-drug combination from Gilead Sciences showed promise during an early-stage trial in eliminating hepatitis C virus, RBC Capital Markets analysts said. The result supports an ongoing Phase II trial of the drug, which consists of Gilead's compounds GS-9256 and GS-9190 plus standard treatments ribavirin and pegylated interferon.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR